1. Scrip
  2. >>Therapy Areas
  3. >>Anticancer

Eisai Joins PROTAC Club Through New Oncology Collab

 
• By Ian Haydock

Japanese firm joins increasing global interest in PROTAC approach to cancer as it links with UK university for drug discovery collaboration.

female scientist working with microscope
Eisai Hunting For New PROTACs • Source: Shutterstock

Eisai Co. Ltd. has climbed aboard the PROTAC research bandwagon gathering speed in the pharma industry globally, signing a new academic research collaboration targeting novel drug discovery in the burgeoning field.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Anticancer

More from Therapy Areas

Scancell Signs UK Match-Making Pact For Melanoma Vaccine

 
• By Kevin Grogan

The Oxford group has linked up with the NHS Cancer Vaccine Launch Pad.

Bristol’s Opdivo + Yervoy Gets FDA Liver, Colorectal Cancer Nods

 
• By Joseph Haas

Bristol Myers Squibb notched two approvals in one week for its immuno-oncology combination, pitting the regimen head-to-head with Keytruda in a subset of CRC and with two combos in HCC.

J&J’s Icotrokinra Scores In Important Adolescent Patient Segment

 
• By Alaric DeArment

The company presented positive Phase III data from a subset analysis of ICONIC-LEAD comprising patients with moderate-to-severe plaque psoriasis.